Observational data also suggest that perioperative PDE5 inhibitor use may reduce the pro-metastatic effects of surgical stress by limiting the expansion of immunosuppressive myeloid cells, further supporting their role alongside other cancer treatments (23). The gene discussed is PDE5A; the disease is cancer.